A Trial of the Efficacy and Safety of a Fixed Dose of SEP‑363856 in Adults With Generalized Anxiety Disorder

Sponsor ID
382-201-00033
Clinicaltrials.gov ID
EudraCT ID
N/A
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Study Contact Information
Recruiting
Sponsor ID
382-201-00033

Study Summary

This is a global, phase 3, randomized, double-blind, parallel-group, 2-arm, placebo controlled, multicenter trial designed to compare the efficacy, safety and tolerability of a fixed dose of SEP-363856 (75 millligrams per day \[mg/day\]) to placebo over an 8-week double-blind treatment period in adults with generalized anxiety disorder (GAD).

Additional Study Details

Phase
Phase 3
Study Drug
Drug: SEP-363856
Type
Interventional
Masking
Triple
Estimated Enrollment
384
Additional Study Details

Inclusion and Exclusion Criteria

Inclusion Criteria

  • Key Inclusion Criteria
  • 1. Male or female participants at least 18 years of age at the time of informed consent

Exclusion Criteria

Locations

Location
Status
Location
IMA Clinical Research - Phoenix
Phoenix, Arizona, United States, 85012
Status
Recruiting
Location
Calneuro Research Group
Los Angeles, California, United States, 90025
Status
Recruiting
Location
Anderson Clinical Research
Redlands, California, United States, 92374
Status
Recruiting
Location
Schuster Medical Research Institute SMRI
Sherman Oaks, California, United States, 91403-1747
Status
Recruiting
Location
Concierge Clinical Trials
Valley Village, California, United States, 91607
Status
Recruiting
Location
Velocity Clinical Research - Hallandale Beach
Hallandale, Florida, United States, 33009
Status
Recruiting
Showing {first} - {last} of {total} Results